Spero Therapeutics Inc (SPRO) Receives a Rating Update from a Top Analyst

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Spero Therapeutics Inc (SPROResearch Report) yesterday. The company’s shares closed on Friday at $12.69.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.3% and a 52.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Currently, the analyst consensus on Spero Therapeutics Inc is a Moderate Buy with an average price target of $27, which is an 112.8% upside from current levels. In a report issued on May 9, Cantor Fitzgerald also maintained a Buy rating on the stock with a $27 price target.

See today’s analyst top recommended stocks >>

Based on Spero Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $10.6 million. In comparison, last year the company had a GAAP net loss of $10.64 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206.